SCHEMBL23949547

SCHEMBL23949547

CC(C)(C)OC(=O)NCC(O)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.53
PRMT5 O14744 1/20 0.49
WDR77 Q9BQA1 1/20 0.49
DGAT1 O75907 1/20 0.40
USP30 Q70CQ3 1/20 0.39
ESR2 Q92731 1/20 0.38
CA1 P00915 4/20 0.37
CA2 P00918 4/20 0.37
CA9 Q16790 4/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
F2 P00734 1/20 0.36
F11 P03951 1/20 0.36
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
SYK P43405 1/20 0.36
SERPINE1 P05121 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1141513 0.88 AAK1 (0.55) AAK1PRMT5WDR77DGAT1USP30
SCHEMBL2553319 0.88 AAK1 (0.55) AAK1PRMT5WDR77DGAT1USP30
SCHEMBL2560306 0.88 AAK1 (0.55) AAK1PRMT5WDR77DGAT1USP30
SCHEMBL15092398 0.86 AAK1 (0.53) AAK1PRMT5WDR77DGAT1USP30
SCHEMBL15092358 0.86 AAK1 (0.51) AAK1PRMT5WDR77DGAT1USP30
SCHEMBL2550288 0.86 AAK1 (0.51) AAK1PRMT5WDR77DGAT1USP30
SCHEMBL25556159 0.85 AAK1 (0.50) AAK1PRMT5WDR77DGAT1USP30
SCHEMBL22604317 0.84 AAK1 (0.51) AAK1PRMT5WDR77DGAT1USP30
SCHEMBL15092530 0.82 AAK1 (0.47) AAK1PRMT5WDR77DGAT1USP30
SCHEMBL17129349 0.81 AAK1 (0.53) AAK1PRMT5WDR77DGAT1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 US disclosed
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 US disclosed
EP-4137481-A1 ARYL OR HETEROARYL DERIVATIVE Teijin Pharma Limited (JP) 2023-02-22 EP disclosed
WO-2021210650-A1 ARYL OR HETEROARYL DERIVATIVE 帝人ファーマ株式会社 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE ARRB1, NR3C2, TRPC6 AAK1 1219/4885PRMT5 4344/4885WDR77 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.